All Stories

  1. Multi-Centric Quality Analysis of Oncological Data in FHIR
  2. Applications of artificial intelligence in nuclear medicine
  3. 18F-FDG PET/CT for the diagnosis of septic shoulder arthritis: metabolic uptake pattern and diagnostic performance
  4. [18F]FDG PET/CT Imaging Is Associated with Lower In-Hospital Mortality in Patients with Pyogenic Spondylodiscitis—A Registry-Based Analysis of 29,362 Cases
  5. 18F-FDG PET/CT-derived total lesion glycolysis predicts abscess formation in patients with surgically confirmed infective endocarditis: Results of a retrospective study at a tertiary center
  6. Artificial Intelligence and Deep Learning for Advancing PET Image Reconstruction: State-of-the-Art and Future Directions
  7. Head-to-Head Comparison of Dual-Source and Split-Beam Filter Multi-Energy CT versus SPECT/CT for Assessing Lobar Lung Perfusion in Emphysema
  8. Infective Endocarditis: Predictive Factors for Diagnosis and Mortality in Surgically Treated Patients
  9. Targeting neuropeptide receptors for cancer imaging
  10. Diagnostic value of FDG PET/CT imaging in patients with surgically managed infective endocarditis: results of a retrospective analysis at a tertiary center
  11. Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature
  12. Radiation doses from low-dose CT scans in SPECT/CT and PET/CT examinations: A survey in Germany
  13. Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
  14. Dose estimates of occupational radiation exposure during radioguided surgery of Tc-99m-PSMA-labeled lymph nodes in recurrent prostate cancer
  15. Lemierre's syndrome following infectious mononucleosis: an unusual reason for neck pain
  16. Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease
  17. Hope for new developments in the reimbursement of oncological PET/CT in Germany
  18. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
  19. Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis
  20. Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning
  21. Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial
  22. Candida Endocarditis in Patients with Candidemia: A Single-Center Experience of 14 Cases
  23. CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma
  24. FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview
  25. PET/CT und PET/MRT bei Tumoren des Kopf-Hals-Bereichs
  26. CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma
  27. Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma
  28. Evaluation der intratherapeutischen Dosimetrie bei der 177Lu-HA-DOTATATE Therapie neuroendokriner Tumoren mittels SPECT, Ganzkörperszintigraphie und Gammasonde
  29. Non-Hodgkin-Lymphome − PET in Diagnostik und Therapiesteuerung
  30. In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT
  31. Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas
  32. Update: PET/CT und PET/MRT bei Tumoren des Kopf-Hals-Bereiches
  33. Entwicklung eines kompetenzbasierten Lernzielkatalogs Nuklearmedizin für das Studium der Humanmedizin in Deutschland
  34. Cutaneous Manifestation of Sarcoidosis in Lower-Back Tattoo With Increased Uptake of 18F-FDG
  35. Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment
  36. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma
  37. AIDS-Related Central Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-L-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells
  38. Effect of lifelong antibiotic treatment for aortic arch prosthesis infection
  39. Differentiated Thyroid Cancer—Treatment: State of the Art
  40. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.
  41. Nuklearmedizin in Deutschland
  42. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18 F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic
  43. Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension
  44. Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma
  45. Positronenemissionstomographie 2013 in Deutschland
  46. Ga-68-PSMA-PET/CT bei Prostatakarzinom
  47. PET/CT bei CUP-Syndromen
  48. FDG-PET/CT-Diagnostik in der Gastroenterologie
  49. PET/CT bei CUP-Syndromen
  50. Zukünftige Indikationen der PET/CT
  51. FDG-PET/CT in der Nachsorge von kolorektalen Karzinomen
  52. FDG-PET/CT bei Fieber ungeklärter Genese
  53. F-18-Natriumfluorid-PET/CT zur Darstellung koronarer Plaquerupturen
  54. Ga-68-PSMA-PET/CT bei Prostatakarzinom
  55. Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany
  56. Evaluation of transcranial sonographic findings and MIBG cardiac scintigraphy in the diagnosis of idiopathic Parkinson's disease
  57. Is reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson’s disease?
  58. Nuclear medicine training and practice in Germany
  59. Summary Report of the First International Workshop on PET/MR Imaging, March 19–23, 2012, Tübingen, Germany
  60. Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer
  61. Nuclear Medicine in Europe: Education
  62. F-18-FDG-PET Confined Radiotherapy of Locally Advanced NSCLC With Concomitant Chemotherapy: Results of the PET-PLAN Pilot Trial
  63. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
  64. Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson’s disease
  65. Simultaneous Occurrence of Typical Carcinoid and Non–Small-Cell Lung Cancer in the Same Lung Lobe
  66. Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer
  67. FP-CIT SPECT Does Not Predict the Progression of Motor Symptoms in Parkinson’s Disease
  68. Nuklearmedizin in Deutschland
  69. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer
  70. Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors
  71. Skelettdiagnostik mittels 18F-Natriumfluorid-PET und -PET/CT
  72. Brain Tumor Imaging Using p-[123I]Iodo-L-Phenylalanine and SPECT
  73. Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma
  74. Positronenemissionstomographie 2008 in Deutschland – Ergebnisse der Erhebung und Standortbestimmung
  75. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
  76. Risk stratification of solitary pulmonary nodules by means of PET using 18F-fluorodeoxyglucose and SUV quantification
  77. Nonrigid Versus Rigid Registration of Thoracic 18F-FDG PET and CT in Patients with Lung Cancer: An Intraindividual Comparison of Different Breathing Maneuvers
  78. Kranielle und extrakranielle sympathische Lewykörperchen-Degeneration beim Morbus Parkinson entwickeln sich zueinander synchron
  79. FDG-PET–Based Radiotherapy Planning in Lung Cancer: Optimum Breathing Protocol and Patient Positioning—An Intraindividual Comparison
  80. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: A systematic review.
  81. 122. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson’s disease
  82. FDG-PET zur Lymphknoten-Diagnostik des Lungenkarzinoms: Welche SUV-Schwelle ist sinnvoll?
  83. FDG-PET-basierte Bestrahlungsplanung von nicht kleinzelligen Bronchialkarzinomen: Optimales Atemprotokoll und Patientenpositionierung – ein intraindividueller Vergleich
  84. FDG- based GTVs for radiotherapy planning in lung cancer: influence of coregistration on volume size
  85. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data
  86. PET Imaging With p-[I-124]iodo-l-phenylalanine as a New Tool for Diagnosis and Postoperative Control in Patients With Glioma
  87. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial
  88. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson's disease
  89. Para-[123I]iodo-L-phenylalanine in patients with pancreatic adenocarcinoma
  90. Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease
  91. 18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense?
  92. Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-α-methyl-tyrosine for SPECT imaging of gliomas
  93. Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson’s Disease
  94. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease
  95. PET-Plan Studie NSCLC: erste Erkenntnisse aus der Homburger Pilotstudie
  96. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer
  97. Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease
  98. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease
  99. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer
  100. Validation of brain tumour imaging with p-[123I]iodo-l-phenylalanine and SPECT
  101. Diagnostik des Bronchialkarzinoms
  102. Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-d-glucose in human pancreatic carcinoma xenografts and in inflammation models
  103. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
  104. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
  105. Progressive dementia caused by Hashimoto's encephalopathy – report of two cases
  106. Value of FDG PET in the management of NSCLC
  107. p -[ 123 I]iodo-l-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma
  108. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy
  109. Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma
  110. 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography in Target Volume Definition for Radiotherapy of Patients with Non-Small-Cell Lung Cancer
  111. Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-L-phenylalanine for routine brain tumour imaging
  112. Clinical Value of Iodine-123-Alpha-Methyl- l -Tyrosine Single-Photon Emission Tomography in the Differential Diagnosis of Recurrent Brain Tumor in Patients Pretreated for Glioma at Follow-Up
  113. Aussagekraft der Positronen-Emissions-Tomographie mit F-18-Fluordesoxyglukose (FDG-PET) beim Bronchioloalveolarzellkarzinom (BAC)
  114. Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren1 - Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000 -
  115. Isolated Cavitary Pulmonary Nodule and Positron Emission Tomography (PET) with F18 Fluorodesoxyglucose (FDG)
  116. Comparison of Early Pulmonary Changes in 18FDG-PET and CT after Combined Radiochemotherapy for Advanced Non-Small-Cell Lung Cancer: A Study in 15 Patients
  117. Stellenwert der Positronen-Emissions-Tomographie mit 18-Fluor-Desoxyglukose (FDG-PET) in der Rezidivdiagnostik des Bronchialkarzinoms
  118. Influence of diabetes mellitus on regional cerebral glucose metabolism and regional cerebral blood flow
  119. Influence of single-photon-transmission scan duration measured with the ECAT ART PET-scanner
  120. 18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis
  121. Diagnostische Aussagekraft der Positronen-Emissions-Tomographie (PET) bei zerebralen Metastasen von Bronchialkarzinomen
  122. Neuropsychological Impairment Correlates With Hypoperfusion and Hypometabolism but Not With Severity of White Matter Lesions on MRI in Patients With Cerebral Microangiopathy
  123. Long-Term Side Effects after High Dose Radioiodine Therapy in Thyroid Carcinoma Patients
  124. Influence of Right Ventricular Stimulation Site on Left Ventricular Function in Atrial Synchronous Pacing
  125. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
  126. A Method of Correlating and Merging Cerebral Morphology and Function by a Special Head Holder
  127. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose